AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37738237
Drug: selfBACK app
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: selfBACK app adjunct to usual care
Trial: 34518253
Drug: e-Help website
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: e-Help website adjunct to usual care
Trial: 35641010
Drug: Standard recommended
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard recommended treatment regimen of chronic stable heart failure
Trial: 35791797
Drug: Tegoprazan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tegoprazan (50 mg) based triple therapy (TPZ)
Trial: 35791797
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg) based triple therapy (LPZ)
Trial: 34374027
Drug: SHR0302 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 4 mg once daily
Trial: 37464978
Drug: SHR0302 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR0302 8 mg once daily
Trial: 33054769
Drug: Some anti-diabetic
RxNorm normalized name: Diabetic Tussin EX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Some anti-diabetic medications
Trial: 39006430
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for four weeks
Trial: 35044810
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel (wP) followed by doxorubicin and cyclophosphamide
Trial: 38479746
Drug: Oral Pre-Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Pre-Exposure Prophylaxis (PrEP)
Trial: 36050704
Drug: Ketorolac injection
RxNorm normalized name: ketorolac Injection
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac injection
Trial: 37118707
Drug: Triamcinolone injection
RxNorm normalized name: triamcinolone Injection
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone injection
Trial: 32694619
Drug: sHDCT/ASCT (salvage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sHDCT/ASCT (salvage high-dose chemotherapy and autologous stem cell transplantation) with lenalidomide maintenance (10 mg/day) after 3 Rd reinduction cycles (lenalidomide 25 mg, day 1–21; dexamethasone 40 mg, day 1, 8, 15, and 22; 4-week cycles)
Trial: 38305378
Drug: Vancomycin (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vancomycin (125 mg 4 times daily for 10 days)
Trial: 32571567
Drug: Uninterrupted (or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uninterrupted (or minimally interrupted) direct oral anticoagulants (DOACs)
Trial: 32571567
Drug: Continuous vitamin
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous vitamin K antagonists
Trial: 32482433
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise (TE) program in combination with the integrated neuromuscular inhibition technique (INIT)
Trial: 33168234
Drug: Optimized delayed-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized delayed-release and extended-release methylphenidate (DR/ER‐MPH)
Trial: 33576545
Drug: Oxycodone/Acetaminophen
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone/Acetaminophen
Trial: 35013131
Drug: Lisdexamfetamine dimesylate
RxNorm normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lisdexamfetamine dimesylate (50 mg)
Trial: 35058090
Drug: Intraoperative injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative injection of 10 ml (133 mg) liposomal bupivacaine
Trial: 32681303
Drug: Aerobic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerobic and resistance exercise intervention (supervised, moderate-vigorous, thrice weekly for 16 weeks)
Trial: 32703288
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT)‐based depression prevention
Trial: 36432607
Drug: 8 mg·kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg·kg bw−1 of caffeine (CF8)
Trial: 35460400
Drug: Estrogen valerate
RxNorm normalized name: valerate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen valerate pretreatment (2 mg twice a day from Day 7 after ovulation to Day 2 of the next menstrual cycle)
Trial: 34663095
Drug: Concurrent partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent partner treatment with oral metronidazole (400 mg) and 2% clindamycin cream applied topically to penile skin, both twice daily for 7 days.
Trial: 34663095
Drug: Concurrent partner
RxNorm normalized name: Milkthistle Fruit (Silybum Marianum L. Gaertner)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent partner treatment
Trial: 32250461
Drug: Current use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current use of antidepressants (overall)
Trial: 33506929
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus GG (L. rhamnosus GG) administered postoperatively for 30 days
Trial: 33891478
Drug: Neoadjuvant chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemoradiotherapy (5 weekly cycles of carboplatin and paclitaxel with concurrent radiotherapy at 41.4 Gy in 23 fractions, 5 days per week) followed by surgery
Trial: 32936533
Drug: Test metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test metformin hydrochloride tablet (0.25 g)
Trial: 32936533
Drug: Reference metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference metformin hydrochloride tablet (0.25 g)
Trial: 36440744
Drug: Action observation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Action observation therapy
Trial: 36440744
Drug: Mirror therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirror therapy and action observation
Trial: 32294394
Drug: Greek yogurt
RxNorm normalized name: Greek pitch
DrugBank: Rosin (DB11165)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greek yogurt with granola (150 kcal, 9.2 g protein, 2.6 g fat, 2.0 g dietary fibre, and 21.5 g available carbohydrate/100 g)
Trial: 32294394
Drug: Cultured coconut
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cultured coconut product with granola (146 kcal, 3.2 g protein, 3.2 g fat, 5.6 g dietary fibre, and 21.9 g available carbohydrate/100 g)
Trial: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EHA cream (1% ectoine and 0.1% hyaluronic acid), applied twice daily for 4 weeks
Trial: 36038984
Drug: Vehicle cream,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle cream, applied twice daily for 4 weeks
Trial: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EHA cream (1% ectoine and 0.1% hyaluronic acid)
Trial: 36038984
Drug: EHA cream
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EHA cream
Trial: 32672654
Drug: Scleral patch
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Scleral patch graft (SPG) technique
Trial: 36401133
Drug: Nivolumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab plus chemotherapy (NIVO + Chemo)
Trial: 33058746
Drug: Complex decongestive
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex decongestive therapy (CDT) including manual lymphatic drainage (MLD) before bandaging, 15 sessions over 3 weeks.
Trial: 33058746
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (ST) including compressive multilayer bandaging and exercise training, 15 sessions over 3 weeks.
Trial: 32742443
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy
Trial: 34344672
Drug: HCQ 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCQ 200 mg/day + BHH 8 mg/8 hours
Trial: 35765728
Drug: 30 ml
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 ml of 0.3% ropivacaine
Trial: 35765728
Drug: 40 ml
RxNorm normalized name: hydrogen peroxide 40 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 ml of 0.3% ropivacaine
Trial: 33242998
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous insulin infusion (CSII) with U-500R
Trial: 33242998
Drug: Subcutaneous injection
RxNorm normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injection (SC) of U-500R
Trial: 32086599
Drug: CHO‐L (carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO‐L (carbohydrate loaded)
Trial: 34678198
Drug: Capsular group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsular group A meningococcal conjugate vaccine (MenA)
Trial: 35410189
Drug: Monthly Clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly Clinical Supervision for up to two years
Trial: 33753657
Drug: Sealants placed
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants placed with bonding agent
Trial: 33753657
Drug: Sealants placed
RxNorm normalized name: thrombin
DrugBank: Thrombin (DB11300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sealants placed without bonding agent
Trial: 35899211
Drug: 5% topical
RxNorm normalized name: BP 5% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% topical minoxidil (MX) alone, once daily
Trial: 35899211
Drug: Minoxidil plus
RxNorm normalized name: Minoxidil
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minoxidil plus oral spironolactone (SPT) 80–100 mg daily
Trial: 33115487
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (manual therapy)
Trial: 33217416
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume mechanical ventilation (3 mL/kg 5 times/min, with positive end expiratory pressure of 5 cm H2O) during CPB
Trial: 33034145
Drug: Piroxicam (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (single dose 1–2 hours before frozen-thawed ET)
Trial: 33034145
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered at the same time as piroxicam)
Trial: 32503502
Drug: New oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New oral composition
Trial: 35110393
Drug: CVN424 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVN424 (1 mg to 225 mg single doses; 25, 75, or 150 mg repeated daily doses for 7 days)
Trial: 35110393
Drug: CVN424 (dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVN424 (dosing after a standardized high-fat meal)
Trial: 35110393
Drug: CVN424 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVN424 (various doses)
Trial: 33038007
Drug: Topical niacinamide
RxNorm normalized name: niacinamide Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical niacinamide
Trial: 35568312
Drug: Active HD-tDCS
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active HD-tDCS (twice a day, 30-min, 3-mA) plus respiratory rehabilitation
Trial: 33855355
Drug: Intermittent two-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent two-drug regimens (2-DRs) given 4-5 days a week
Trial: 33855355
Drug: Intermittent two-drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent two-drug regimens (2-DRs)
Trial: 36260786
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment with 5-fluorouracil and folinic acid or capecitabine plus oxaliplatin (FOLFOX6 or CAPEOX; Arm 1)
Trial: 36260786
Drug: Serial ctDNA
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serial ctDNA surveillance with delayed adjuvant therapy (Arm 2)
Trial: 34588245
Drug: eMMa (electronic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: eMMa (electronic medication management support system)
Trial: 36038003
Drug: Tanezumab 10
RxNorm normalized name: tanezumab
DrugBank: Tanezumab (DB12335)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tanezumab 10 mg subcutaneously
Trial: 33190355
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake at breakfast (10 g increase)
Trial: 33190355
Drug: Protein intake
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Protein intake at lunch (10 g increase)
Trial: 32938772
Drug: All patients
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients post-discontinuation (≤30 days)
Trial: 35410753
Drug: SID142 (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SID142 (200 mg cilostazol and 160 mg Ginkgo biloba leaf extract, once daily)
Trial: 35410753
Drug: Renexin (cilostazol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renexin (cilostazol and Ginkgo biloba leaf extract, twice daily)
Trial: 33794293
Drug: TP53 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: TP53 gene alteration pre-treatment and at C2D1
Trial: 33794293
Drug: RB1 gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: RB1 gene alteration pre-treatment and at C2D1
Trial: 33794293
Drug: PTEN gene
RxNorm normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTEN gene alteration pre-treatment and at C2D1
Trial: 33794293
Drug: Patients who
RxNorm normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who were positive pre-treatment and converted to undetectable
Trial: 35557278
Drug: BAPN (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAPN (300 mg/kg/day in water)
Trial: 32760097
Drug: Regular-exercise group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular-exercise group (conventional physical therapy and scapular muscle strengthening exercises)
Trial: 36109008
Drug: Sodium Citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Citrate (SC, 500 mg/kg body mass)
Trial: 36109008
Drug: Sodium Bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium Bicarbonate (SB, 300 mg/kg body mass)
Trial: 32827501
Drug: Intranasal AVP
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal AVP (20 IU)
Trial: 36131289
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive therapy (iCBT) involving 7 weekly online modules delivered via a perinatal mental healthcare app
Trial: 36131289
Drug: Internet-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-based cognitive therapy (iCBT)
Trial: 32810383
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg teneligliptin
Trial: 35960044
Drug: Lidocaine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (1 mg/kg intravenously during anesthesia induction, then continuously pumped at 1 mg/kg/h until operation)
Trial: 32039635
Drug: Brief Behavioral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Brief Behavioral Therapy for Insomnia (BBTi)
Trial: 35508338
Drug: Sodium valproate
RxNorm normalized name: sodium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sodium valproate 20 mg/kg daily
Trial: 32038026
Drug: Six-month dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Six-month dual antiplatelet therapy (DAPT) after BP-SES implantation
Trial: 32038026
Drug: Twelve-month dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve-month dual antiplatelet therapy (DAPT) after BP-SES implantation
Trial: 32522198
Drug: Early intravenous
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intravenous metoprolol
Trial: 34431174
Drug: Intervention twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention twice per week (20-30 min sessions for 10 weeks, 1000 trials; 400-600 min total)
Trial: 33628717
Drug: Propolis (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis (75 mg three times a day)
Trial: 35386013
Drug: FMXIN001 (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMXIN001 (intranasal powder-based naloxone formulation)
Trial: 35386013
Drug: Narcan® (nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narcan® (nasal liquid spray)
Trial: 32472417
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for MBC patients with low RS
Trial: 32472417
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy for FBC patients with low RS
Trial: 32472417
Drug: Overall chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall chemotherapy rates
Trial: 86266805
Drug: Z5: streptomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z5: streptomycin plus isoniazid plus pyrazinamide twice weekly for 2 months without rifampin
Trial: 34051342
Drug: Beetroot juice
RxNorm normalized name: tamarind juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beetroot juice (BRJ) - 70 ml dose per day for 20 days (12.5 mmol nitrate per day; n = 11)
Trial: 36461695
Drug: Pre-urodynamic single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-urodynamic single-dose Levofloxacin (500 mg administered one hour before the urodynamic study)
Trial: 36461695
Drug: Post-urodynamic Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Post-urodynamic Levofloxacin (500 mg once daily for three days following the urodynamic study)
Trial: 33599247
Drug: Ivermectin 6
RxNorm normalized name: ivermectin 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 6 mg regime
Trial: 33599247
Drug: Ivermectin 12
RxNorm normalized name: Ivermectin 12 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin 12 mg regime (given Q84 h for 2 weeks)
Trial: 33599247
Drug: Ivermectin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivermectin (both doses)
Trial: 36173481
Drug: High Na+
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Na+ (60 mmol L-1 sodium)
Trial: 36173481
Drug: Low Na+
RxNorm normalized name: calcium chloride / glucose / lactate / magnesium chloride / sodium chloride Intraperitoneal Solution [Dianeal Low Calcium 1.5]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Na+ (21 mmol L-1 sodium)
Trial: 32398852
Drug: Simultaneous double-protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simultaneous double-protocol therapy (intravitreal dexamethasone implant and ranibizumab)
Trial: 32512517
Drug: HIV-1 RNA
RxNorm normalized name: Remune HIV-1
DrugBank: Remune (DB17772)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 RNA ≥5 log10 copies/ml
Trial: 35768119
Drug: Preoperative carbohydrate-loading
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative carbohydrate-loading drinks (4×200 mL evening before surgery and 2×200 mL the morning of surgery) and early postoperative nutritional protein supplement drinks two times per day for 14 days
Trial: 32584754
Drug: Advertisement cue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advertisement cue combination (financial security and taking control of one's future)
Trial: 33086160
Drug: Mixed amphetamine
RxNorm normalized name: mixed amphetamine salts 5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mixed amphetamine salts-extended-release (MAS-ER), titrated up to 80 mg daily
Trial: 35247334
Drug: Topical LHA510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical LHA510 administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Trial: 35247334
Drug: Vehicle (placebo)
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle (placebo) administered twice a day for 8 weeks and then 3 times a day for the last 4 weeks
Trial: 35247334
Drug: Topical LHA510
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical LHA510